Velcade for Injection Showed Positive Activity Across Variety of Lymphomas

Millennium Pharmaceuticals has announced Velcade study results for the treatment of patients with indolent and mantle cell non-Hodgkin's lymphomas, and Waldenstom's Macroglobulemia at the 9th International Conference of Malignant Lymphoma in Lugano, Switzerland.

Interim study results were reported from the multicenter, Phase II trial of weekly versus twice- weekly dosing of Velcade in combination with rituximab, in patients with indolent lymphomas. In these patients, who were previously pretreated with chemotherapy and rituximab, response rates were similar in both arms (35 and 41 percent) and the safety profile improved with the weekly schedule.